Zobrazeno 1 - 10
of 53
pro vyhledávání: '"J. Cather"'
Publikováno v:
Songklanakarin Journal of Science and Technology (SJST), Vol 46, Iss 1, Pp 16-23 (2024)
We are completely aware of the fact that ternary algebraic structures in some way naturally occur in diverse fields of theoretical and mathematical physics, computer science, especially in ternary operators in Java and Python, ternary logic applied
Externí odkaz:
https://doaj.org/article/9f9231a0aa094e9b9d4ea7a553621d50
Publikováno v:
Applied Water Science, Vol 14, Iss 3, Pp 1-15 (2024)
Abstract Poor raw water quality has led science and technology research to explore more environmentally friendly water treatment methods, such as advanced oxidation processes. Ferrate (VI) salts have been regarded as a new green oxidant, cost-effecti
Externí odkaz:
https://doaj.org/article/033dfbc91e3c45e7827c365aa2b30be4
Autor:
Yves Poulin, J. Cather, Rm Stevens, Rm Day, Carle Paul, Giampiero Girolomoni, C. Hu, Jeffrey J. Crowley, Melinda Gooderham, K. Shah, Ulrich Mrowietz, Carlos Ferrándiz, Ab Gottlieb
Publikováno v:
British Journal of Dermatology. 173:1387-1399
SummaryBackground Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of apremilast 30 mg twice daily for moderate-to-severe plaque psoriasis.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Alice B. Gottlieb, James G. Krueger, Ajay Nirula, Gregory Kricorian, Darryl Toth, Andrew Blauvelt, Kim A. Papp, Joanne Li, Kristian Reich, Carle Paul, Diamant Thaçi, Cassandra E Milmont, Richard G. Langley, Chris B. Russell, Paul Klekotka, W. Baran, Chantal Bolduc, J. Cather
Publikováno v:
The British journal of dermatology. 175(2)
SummaryBackground The interleukin-17 cytokine family plays a central role in psoriasis pathogenesis. Objectives To evaluate the efficacy and safety of brodalumab, a human anti-interleukin-17 receptor antibody, in treating patients with moderate-to-se
Autor:
P. Prakash, J. Catherine Grace John, T. Merita Anto Britto, S. Rubila, A. Kingson Solomon Jeevaraj
Publikováno v:
Songklanakarin Journal of Science and Technology (SJST), Vol 44, Iss 4, Pp 979-986 (2022)
The current study used ultrasound-assisted chemical precipitation to create zinc doped beryllium oxide (BeO) nanoparticles. X-ray diffraction (XRD) and scanning electron microscopy (SEM) were used to characterize the synthesized samples. The effect
Externí odkaz:
https://doaj.org/article/9c83ef66b2dc4c75ab6f5c6ba71a9943
Autor:
M. Sebastian, Carlos Ferrándiz, Jeffrey J. Crowley, Giampiero Girolomoni, Robert M. Day, J. Cather, M. Beylot-Barry, H. ChiaChi, Melinda Gooderham
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 142:S670-S671
Introduction L’apremilast (APR), un inhibiteur intracellulaire oral de la phosphodiesterase 4, regule les mediateurs inflammatoires impliques dans le psoriasis. Patients et methodes Des patients atteints de psoriasis en plaques modere a severe –
Publikováno v:
Journal of Engineering, Vol 2022 (2022)
The dielectric characteristics of barium oxide: Therm500 nanofluids were investigated at a static frequency in this study. Barium oxide: Therm500 nanofluids are made by dispersing barium oxide nanoparticles in Therm500 (base fluid) using a sonicator.
Externí odkaz:
https://doaj.org/article/f21b09b3fc104c8aa820d0a230b95cdf
Autor:
Y. Poulain, Jeffrey J. Crowley, C. Hu, G. Giromoloni, U. Mrowietz, J. Cather, Carlos Ferrándiz, R. Stevens, Carle Paul, Melinda Gooderham, Robert M. Day
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 141:S291
Introduction L’apremilast (APR), inhibiteur oral de la phosphodiesterase 4 agit au niveau intracellulaire en modulant l’activite des cytokines pro-inflammatoires. Materiel et methodes Dans ESTEEM 2, les patients avec un psoriasis en plaque modere
Publikováno v:
American journal of hematology. 58(1)
Four patients with late stage cutaneous T cell lymphoma (IB-IVA) who had failed at least two previous therapies were treated with DAB389IL2 at 9 or 18 microg/kg as 15-min intravenous infusions daily for 5 days every 3 weeks for eight cycles. Mild vas